| The CST complex mediates end protection at double-strand breaks and promotes PARP inhibitor sensitivity in BRCA1-deficient cells M Barazas, S Annunziato, SJ Pettitt, I de Krijger, H Ghezraoui, SJ Roobol, ... Cell reports 23 (7), 2107-2118, 2018 | 135 | 2018 |
| Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer S Annunziato, JR de Ruiter, L Henneman, CS Brambillasca, C Lutz, ... Nature Communications 10 (1), 397, 2019 | 71 | 2019 |
| In situ CRISPR‐Cas9 base editing for the development of genetically engineered mouse models of breast cancer S Annunziato, C Lutz, L Henneman, J Bhin, K Wong, B Siteur, ... The EMBO journal 39 (5), e102169, 2020 | 48 | 2020 |
| Truncated FGFR2 is a clinically actionable oncogene in multiple cancers D Zingg, J Bhin, J Yemelyanenko, SM Kas, F Rolfs, C Lutz, JK Lee, ... Nature 608 (7923), 609-617, 2022 | 40 | 2022 |
| MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling D Zimmerli, CS Brambillasca, F Talens, J Bhin, R Linstra, L Romanens, ... Nature communications 13 (1), 6579, 2022 | 34 | 2022 |
| The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review J Bosschieter, C Lutz, LI Segerink, AN Vis, EC Zwarthoff, ... Epigenomics 10 (5), 673-687, 2018 | 34 | 2018 |
| Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers P Ter Brugge, SC Moser, I Bièche, P Kristel, S Ibadioune, A Eeckhoutte, ... Nature Communications 14 (1), 1958, 2023 | 7 | 2023 |
| MYC promotes immune-suppression in TNBC via inhibition of IFN signaling D Zimmerli, CS Brambillasca, F Talens, J Bhin, A Bhattacharya, ... bioRxiv, 2021.02. 24.432659, 2021 | 6 | 2021 |
| A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression SJ Hutten, R de Bruijn, C Lutz, M Badoux, T Eijkman, X Chao, M Ciwinska, ... Cancer cell 41 (5), 986-1002. e9, 2023 | 4 | 2023 |
| Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity S Prekovic, T Chalkiadakis, M Roest, D Roden, C Lutz, K Schuurman, ... EMBO Molecular Medicine 15 (12), e17737, 2023 | 1 | 2023 |
| Abstract LB_B04: Deciphering FGFR3-TACC3 oncogenic fusions J Yemelyanenko, J Bhin, S Klarenbeek, JY Song, C Lutz, M Ven, ... Molecular Cancer Therapeutics 22 (12_Supplement), LB_B04-LB_B04, 2023 | 1 | 2023 |
| Abstract IA012: Mammary epithelial architecture modulates field cancerization H Messal, C Scheele, E Lips, C Lutz, S Hutten, P Kristel, C Vlahu, ... Cancer Prevention Research 15 (12_Supplement_1), IA012-IA012, 2022 | 1 | 2022 |
| Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers D Zingg, J Bhin, J Yemelyanenko, SM Kas, F Rolfs, C Lutz, JK Lee, ... Nature 609 (7929), E13-E13, 2022 | 1 | 2022 |
| Abstract A062: Somatic engineering of rat models to recapitulate human breast cancer evolution and heterogeneity C Lutz, JY Song, HA Messal, M Badoux, T Eijkman, B de Klein, ... Cancer Research 84 (3_Supplement_1), A062-A062, 2024 | | 2024 |
| Abstract PR10: Mammary epithelial architecture modulates field cancerization HA Messal, C Cleyp0ol, C Lutz, S Hutten, E Lips, J Jonkers, J Wesseling, ... Cancer Research 84 (3_Supplement_1), PR10-PR10, 2024 | | 2024 |
| Truncated FGFR2-a clinically actionable oncogene in multiple cancers DK Zingg, J Bhin, J Yemelyanenko, SM Kas, C Lutz, CC Lin, ... Cancer Research 83 (7_Supplement), 3488-3488, 2023 | | 2023 |
| Abstract PR006: A living biobank of patient-derived ductal carcinoma in situ (DCIS) Mouse-INtraDuctal (MIND) xenografts identifies multiple risk factors of invasive progression SJ Hutten, R de Bruijn, C Lutz, M Badoux, T Eijkman, X Chao, M Ciwinska, ... Cancer Prevention Research 15 (12_Supplement_1), PR006-PR006, 2022 | | 2022 |
| A living biobank of patient-derived ductal carcinoma in situ (DCIS) Mouse-INtraDuctal (MIND) xenografts identifies multiple risk factors of invasive progression SJ Hutten, R de Bruijn, C Lutz, M Badoux, T Eijkman, X Chao, M Ciwinska, ... Cancer Prevention Research 15 (12), 2022 | | 2022 |
| Abstract PR003: Pioneering genetic rat models of Ductal Carcinoma in situ (DCIS) C Lutz, M Badoux, T Eijkman, B de Klein, JY Song, L Henneman, ... Cancer Prevention Research 15 (12_Supplement_1), PR003-PR003, 2022 | | 2022 |
| Pioneering genetic rat models of Ductal Carcinoma in situ (DCIS). C Lutz, M Badoux, T Eijkman, B de Klein, JY Song, L Henneman, ... Cancer Prevention Research 15 (12), 2-3, 2022 | | 2022 |
